Global Parenteral Nutrition Market - Focused Insights 2024-2029

MARKET INSIGHTS

The global parenteral nutrition market was valued at USD 8.46 billion in 2023 and is projected to reach USD 13.60 billion by 2029, with a CAGR of 8.24% during the forecast period. This expansion is driven by the rising incidence of chronic illnesses such as cancer and gastrointestinal disorders, an increase in cases of malnutrition, and an aging population facing challenges with nutrient absorption. Innovations in parenteral nutrition formulations tailored to specific patient needs have enhanced safety and effectiveness, further promoting their adoption.

MARKET DEFINITION

Parenteral nutrition (PN) is a medical method that delivers essential nutrients, including proteins, carbohydrates, fats, vitamins, minerals, and trace elements, directly into the bloodstream through an intravenous (IV) catheter. It is suitable for patients of all ages, from infants to adults, who are unable to obtain adequate nutrients through traditional or tube feeding. This sterile liquid formula supports proper nutritional status by completely bypassing the digestive system, ensuring that patients receive the vital nutrients essential for health and recovery.

MARKET TRENDS & DRIVERS

Rising Use of Premixed PN Formulations

The adoption of premixed PN formulations is increasing, highlighting the healthcare industry's emphasis on safety, efficiency, and cost-effectiveness in providing nutritional support. Premixed PN solutions are ready-to-use standardized nutrient formulas that eliminate the need for compounding or manual preparation in healthcare facilities. This convenience is particularly valuable in hospitals and clinics where prompt action is critical, such as in emergency or intensive care units.

The preparation process is simplified with premixed formulations, allowing healthcare providers to save time and reduce the likelihood of human error associated with manually mixing nutrients, an essential aspect of ensuring patient safety. A significant factor driving the growth of premixed PN is the greater sterility and stability they provide. Manufactured in controlled environments, these formulations adhere to strict quality and safety standards, significantly lowering the risk of contamination often associated with in-house compounding. Such sterility is especially vital in PN, where even minor contamination can lead to serious complications due to direct intravenous delivery.

Utilizing premixed PN solutions also facilitates easier storage, handling, and transportation for healthcare facilities, as these formulations generally have extended shelf lives and standardized packaging, making them convenient and versatile across various care environments.

Growing Issue of Premature Births

The rising rates of premature births worldwide are increasing the demand for specialized neonatal care, particularly PN. Infants born before 37 weeks of gestation often struggle to take in or absorb sufficient nutrition through oral or enteral means due to their underdeveloped gastrointestinal systems, making PN essential for their growth and development. Escalating rates of premature births, especially in regions like Sub-Saharan Africa and certain areas of the U.S., underscore the necessity for nutrient-rich PN solutions that promote growth, brain development, and immune function during these crucial early life stages. In response to these challenges, advancements in PN formulations that are enriched with vital nutrients such as trace elements, fatty acids, and micronutrients have enhanced the quality of neonatal care. These improvements help to minimize complications like nutrient imbalances and liver disease, thereby increasing survival rates and long-term outcomes for preterm infants in neonatal intensive care units (NICUs). As the prevalence of premature births continues to grow, there is an increasing focus on enhancing the quality and safety of PN to provide better support for these at-risk infants.

GLOBAL PARENTERAL NUTRITION MARKET INSIGHTS

• Product Insights: The global market for parenteral nutrition is divided into three categories: macronutrients, automated compounds, and micronutrients. The macronutrients segment represented the largest market share of 66% in 2023. In the context of parenteral nutrition, macronutrients—including carbohydrates, lipids, and amino acids—are the foundation of nutritional formulations designed for patients with impaired digestive functions or specific dietary needs. Demand for PN with a balanced composition of macronutrients is on the rise, driven by progress in clinical insights and patient-centered requirements. Multichamber bags (MCBs) are gaining popularity as they offer pre-compounded formulations of glucose, amino acids, and lipids, simplifying preparation and minimizing errors in both inpatient and outpatient environments. These bags are available in dual- and tri-chamber designs, with tri-chamber bags incorporating all three key macronutrients, which lowers manipulation and enhances safer administration. The emphasis on optimizing macronutrients aligns with ongoing trends in the PN market, which is expected to expand as healthcare providers and manufacturers collaborate to enhance product safety, standardization, and personalized care solutions.
• Nutrition Insights: The global market for PN is divided into ready-to-use (RTU) standard commercial PN and compounded PN. The compounded PN sector is experiencing remarkable growth, with the highest CAGR of 10.33% projected during the forecast period. Compounded parenteral nutrition is essential in the global PN landscape, offering customized nutritional solutions for patients with specific medical requirements. Unlike standard PN formulations, compounded PN is tailored, enabling healthcare providers to modify macronutrients, micronutrients, and fluid volumes to cater to individual patient needs. This approach is particularly beneficial for those with unique metabolic demands or complex conditions, such as critically ill patients or individuals with organ dysfunction, who require precise nutrient management. Personalizing nutritional content enhances the effectiveness of treatments, minimizes the risk of nutrient imbalances, and improves overall patient outcomes, making compounded PN a rapidly expanding segment within the wider PN market.
• Patient Group Insights: The global parenteral nutrition market is further segmented by patient group, comprising adults and pediatric patients. The adult segment is the largest, capturing the most significant market share in 2023. The increasing number of adults dependent on parenteral nutrition, due to conditions needing intravenous nutritional support, such as short bowel syndrome, pancreatitis, Crohn's disease, and enterocutaneous fistulas, drives this growth. Total Parenteral Nutrition (TPN) is vital for adults who cannot absorb nutrients through the gastrointestinal system. As malnutrition related to various health issues rises, thorough nutritional assessments and TPN interventions are essential for enhancing patient outcomes. The establishment of standardized diagnostic frameworks will further improve the management of adult malnutrition within healthcare systems.
• Indication Insights: In terms of indications, the short-term segment commands the largest share of the global parenteral nutrition market. The short-term PN market has developed to better meet the metabolic requirements of critically ill patients. Fat-based solutions, as opposed to those high in glucose, help reduce inflammation and stabilize blood sugar, suggesting they may lower risks like hyperglycemia. This progress emphasizes the need for tailored PN solutions. Short-term PN acts as a transitional support for patients needing immediate stabilization, particularly during preoperative bowel rest. However, the complexity of PN necessitates strict supervision to avoid complications, such as infections and electrolyte imbalances. Particularly in smaller facilities, especially within U.S. hospitals, ensuring safety highlights the importance of thorough training and proper handling of formulations.
• End-User Insights: Regarding end-users, the home care and long-term care segments are experiencing significant growth and show the highest CAGR in the global parenteral nutrition market during the forecast period. This expansion is driven by the increasing population of patients with chronic conditions requiring long-term nutritional support who prefer to receive care at home to enhance their quality of life while minimizing the risk of infections. Home care parenteral nutrition offers an economical solution, enabling patients to manage their health conditions comfortably and reduce healthcare expenses. Likewise, long-term care facilities, such as nursing homes, are progressively adopting parenteral nutrition to cater to an aging population with complex health requirements. Elderly patients with illnesses or age-related conditions that hinder nutrient absorption depend on parenteral nutrition to support their health.

Geographical Insights

In 2023, North America leads the global parenteral nutrition market, holding the largest market share. This growth is largely attributed to the rising incidence of gastrointestinal disorders, such as Crohn's disease, ulcerative colitis, and short bowel syndrome, which require nutritional support through parenteral methods when patients are unable to consume food orally. In addition, the increasing prevalence of chronic diseases supports market expansion. Currently, around 60% of adults in the U.S. have at least one chronic condition, a figure expected to rise significantly, leading to greater dependence on parenteral nutrition to fulfill dietary requirements during treatment. As healthcare systems evolve to meet these growing demands, North America's parenteral nutrition market is set for considerable growth in the years ahead.

COMPETITIVE LANDSCAPE

The global parenteral nutrition market report features exclusive information on 26 vendors. It is characterized by intense competition, with several key players, including Baxter, B. Braun, Fresenius Kabi, JW Pharmaceutical, Sichuan Kelun Pharmaceutical, and Grifols, holding substantial market shares and offering extensive parenteral nutrition portfolios. These companies prioritize innovation to enhance nutrient delivery systems, boost efficiency, and improve patient outcomes. In addition, local and regional players are emerging, particularly in developing markets where there is an increasing demand for effective nutrition management solutions. In regions such as APAC and Latin America, these companies often provide cost-effective solutions tailored to local needs. Furthermore, new firms are placing a growing emphasis on personalized nutrition solutions to meet the specific metabolic needs of individual patients

RECENT VENDOR ACTIVITIES

• In 2023, American Regent launched Potassium Phosphates Injection USP, which serves a similar purpose to Potassium Phosphates. This FDA-approved solution delivers phosphorus in intravenous fluids for both children and adults who are unable to intake adequate phosphorus through food or feeding tubes.
• In 2022, Otsuka Pharmaceutical Co., Ltd. gained approval for ENEFLUID Injection, marking Japan's first peripheral parenteral nutrition solution. This groundbreaking product combines fats, water-soluble vitamins, glucose, electrolytes, and amino acids in a dual-chamber bag, significantly enhancing the company’s product offerings and contributing to its market expansion.